Showing 6491-6500 of 8876 results for "".
- Naftin Gel 2% Approved for Interdigital-Type Tinea Pedishttps://practicaldermatology.com/news/20130702-naftin_gel_2_approved_for_interdigital-type_tinea_pedis/2459507/The FDA approved Naftin (naftifine HCl) Gel 2% for the treatment of interdigital-type tinea pedis from Merz North America. Naftin Gel 2% improves on the current formulation of Naftin Gel 1% by delivering the efficacy of naftifine hydochloride with
- Artefill Shows Efficacy for Atrophic Acne Scars: Datahttps://practicaldermatology.com/news/20130624-artefill_shows_efficacy_for_atrophic_acne_scars_data/2459513/Recently reported data suggest that ArteFill dermal filler is an effective option to treat atrophic acne scars. Suneva Medical shared promising six-month results from its randomized, double-blinded, multi-center, controlled study that evaluated the
- Avène SPF Awarded Skin Cancer Foundation Seal Of Recommendationhttps://practicaldermatology.com/news/20130611-avne_spf_awarded_skin_cancer_foundation_seal_of_recommendation/2459517/The Skin Cancer Foundation approved Avène High Protection Tinted Compact SPF 50 in both shades (Beige and Honey) to carry The Skin Cancer Foundation Active Seal of Recommendation. The coveted Seal signifies that these products have
- Stelara Approved for Self-Administrationhttps://practicaldermatology.com/news/20130611-stelara_approved_for_self-administration/2459518/The FDA has approved Stelara (ustekinumab) for self-administration. Previously intended for subcutaneous administration under the supervision of a physician, Stelara can now be administered by patients at home. The drug is approved for the treatment of adult patients with moderate to severe plaque p
- National Psoriasis Foundation Awards Research Grantshttps://practicaldermatology.com/news/20130610-national_psoriasis_foundation_awards_research_grants/2459519/Six scientists received National Psoriasis Foundation (NPF) research grants totaling $450,000 for projects that aim to discover new treatments and a cure for psoriasis and psoriatic arthritis. Theoharis Theoharides, MD, PhD received a
- Results of SB204 Clinical Study in Acne Releasedhttps://practicaldermatology.com/news/20130605-results_of_sb204_clinical_study_in_acne_released/2459523/Nitric oxide releasing drug candidate SB204 reduces colonization of the acne-causing bacteria Propionibacterium acnes (P. acnes) in the skin of healthy volunteers, according to a recent trial. This study, in combination with Novan Therapeutics' earlier findings regarding sebum production, suggests t
- Two Melanoma Drugs Win FDA Approvalhttps://practicaldermatology.com/news/20130530-two_melanoma_drugs_win_fda_approval/2459528/The FDA approved two new drugs for metastatic or inoperable melanoma, dabrafenib (Tafinlar) and trametinib (Mekinist). Dabrafenib is an inhibitor of the BRAF gene when it carries the so-called V600E mutation. Trametinib inhibits a target known as MEK and is effective primarily against melanomas carr
- Workshops Added to Aesthetic Extender Symposium 2013https://practicaldermatology.com/news/20130524-workshops_added_to_aesthetic_extender_symposium_2013/2459531/Five additional workshops will be held at the Aesthetic Extender Symposium (AES) at the Boca Raton Resort & Club from October 31 - November 3: Friday, November 1, 3:45 - 5:45 PM Innovations in Facial Aesthetic Medicine: Mastering the Art and Science of Injectables Michael Kane, MD & Jason Pozner,
- Actavis to Acquire Warner Chilcotthttps://practicaldermatology.com/news/20130521-actavis_to_acquire_warner_chilcott/2459533/Actavis will acquire Warner Chilcott plc in a stock-for-stock transaction valued at approximately $8.5 billion. If successfully completed, the transaction will create a global specialty pharmaceutical company with approximately $11 billion in combined annual revenue, and the third-largest US special
- AARS and AAP Release Acne Recommendationshttps://practicaldermatology.com/news/20130520-aars_and_aap_release_acne_recommendations/2459536/Evidence-based recommendations for the diagnosis and treatment of pediatric acne were recently published in Pediatrics. These recommendations were developed through the American Acne Rosacea Society (AARS) and endorsed by the American Academy of Pediatrics. The recommendations are a result of a two